Long-term Disease-free Survival after Hepatic Metastasectomy for Urothelial Carcinoma of the Bladder: A Case Report and Review of the Literature

2015 ◽  
Vol 8 ◽  
pp. CMU.S29263
Author(s):  
Nathan A. Brooks ◽  
Laila Dahmoush ◽  
James A. Brown
Keyword(s):  
Case Report ◽  
Urothelial Carcinoma ◽  
Disease Free Survival ◽  
Review Of The Literature ◽  
Free Survival ◽  
Carcinoma Of The Bladder ◽  
Disease Free

Long-term disease-free survival after plasmacytoma of the urethra: a case report and review of the literature

Urology ◽  
1996 ◽  
Vol 48 (1) ◽  
pp. 149-150 ◽  
Author(s):  
Robert M. Mordkin ◽  
Donald G. Skinner ◽  
Alexandra M. Levine
Keyword(s):  
Case Report ◽  
Disease Free Survival ◽  
Review Of The Literature ◽  
Free Survival ◽  
Disease Free

scholarly journals LGALS4 as a Prognostic Factor in Urothelial Carcinoma of Bladder Affects Cell Functions

2019 ◽  
Vol 18 ◽  
pp. 153303381987660 ◽  
Author(s):  
Yu Ding ◽  
Qifeng Cao ◽  
Chen Wang ◽  
Huangqi Duan ◽  
Haibo Shen
Keyword(s):  
Urothelial Carcinoma ◽  
Survival Curve ◽  
Disease Free Survival ◽  
Hub Genes ◽  
Free Survival ◽  
Polymerase Chain ◽  
Carcinoma Of The Bladder ◽  
Bladder Cells ◽  
And Migration ◽  
Disease Free

Background: To identify the hub genes related to urothelial carcinoma of the bladder prognosis and to understand their underlying mechanism. Methods: The expression profiles of 18 pairs of urothelial carcinoma of the bladder patient tissue and paired adjacent tissue obtained from the Cancer Genome Atlas were performed. Weighted gene coexpression network analysis was employed to screen gene modules and hub genes with significant differential expressions in urothelial carcinoma of the bladder. The hub genes expression in urothelial carcinoma of the bladder tissues was validated by reverse transcription-quantitative polymerase chain reaction. The overall survival curve and disease-free survival curve of prognostic factor ( LGALS4) were plotted using the Kaplan-Meier method. Furthermore, LGALS4 messenger RNA and protein expression were also assessed in 2 urothelial carcinoma of the bladder cell lines (T24 and 5637) by quantitative reverse transcription–polymerase chain reaction and Western blot. The functions of urothelial carcinoma of the bladder cells with transfected pcDNA3.1- LGALS4 were identified through MTT assay, plate clone formation assay, flow cytometry, and cell migration experiments. Results: LGALS4 was the hub gene of pink module and it was related to prognosis. Higher LGALS4 expression predicted higher probabilities of overall survival and disease-free survival. Overexpression of LGALS4 in urothelial carcinoma of the bladder cells suppressed cell viability and migration but induced apoptosis. Conclusion: LGALS4 played a critical role in the progression of urothelial carcinoma of the bladder and held a promise to be the biomarker for diagnosis and treatment of urothelial carcinoma of the bladder. It predicted good prognosis of urothelial carcinoma of the bladder and restrained the growth and migration of urothelial carcinoma of the bladder cells.

scholarly journals Extraordinary disease-free survival in a rare malignant extrarenal rhabdoid tumor: a case report and review of the literature

2018 ◽  
Vol 12 (1) ◽  
Author(s):  
Francesco D’Amico ◽  
Alessandra Bertacco ◽  
Maurizio Cesari ◽  
Claudia Mescoli ◽  
Giorgio Caturegli ◽  
...  
Keyword(s):  
Case Report ◽  
Disease Free Survival ◽  
Rhabdoid Tumor ◽  
Review Of The Literature ◽  
Free Survival ◽  
Disease Free ◽  
Extrarenal Rhabdoid Tumor

Resection of Single Metachronous Liver Metastases from Breast Cancer Stage I-II Yield Excellent Overall and Disease-Free Survival. Single Center Experience and Review of the Literature

2015 ◽  
Vol 32 (1) ◽  
pp. 52-59 ◽  
Author(s):  
Céline Vertriest ◽  
Giammauro Berardi ◽  
Federico Tomassini ◽  
Rudy Vanden Broucke ◽  
Herman Depypere ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Liver Metastases ◽  
Metastatic Cancer ◽  
Disease Free Survival ◽  
Stage I ◽  
Review Of The Literature ◽  
Term Survival ◽  
Free Survival ◽  
Disease Free

Purpose: Improved survival after liver resection for breast cancer liver metastases (BCLM) has been proven; however, there is still controversy on predictive factors influencing outcomes. The analysis of factors related to primary and metastatic cancer eventually influencing long-term outcomes and a review of the literature are presented in this report. Methods: Twenty-seven patients diagnosed with metachronous BCLM between 1996 and 2013 were retrospectively reviewed. Patients who had a minimum disease-free interval between primary tumor and liver metastasis of 12 months, no more than 3 liver lesions, no macroscopic extra-hepatic disease and in which systemic therapy showed a good response were included. Results: Twenty-two patients (82%) were initially diagnosed with a stage I-II disease. Twelve patients presented with multiple liver metastases. The 5 years overall survival (OS) rate was 78%, while the 5 years disease-free survival (DFS) rate was 36%. Initial tumor stage III-IV at first diagnosis and number of metastases >1 was significantly associated with a shorter DFS at multivariate analysis (p = 0.03 and p = 0.04 respectively). Patients with multiple lesions had a median DFS of 15 months compared to 47 months in patients with a single lesion (p = 0.03). Conclusions: Resection of single BCLM from primary stage I-II cancer offers very good long-term survival rates and a low morbidity.

Sign in / Sign up

Export Citation Format

Share Document